X0306 4/A 2020-01-07 2020-01-09 1 0001744659 Akero Therapeutics, Inc. AKRO 0001687880 Versant Venture Capital VI, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001777654 Versant Ventures VI GP, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001777652 Versant Ventures VI GP-GP, LLC ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 Common Stock 2020-01-07 4 S 0 14162 20.05 D 2885836 I See Footnote Common Stock 2020-01-08 4 S 0 22368 19.8 D 2863468 I See Footnote Common Stock 2020-01-09 4 S 0 16527 20.21 D 2846941 I See Footnote The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan. These sales were executed in multiple trades at prices ranging from $19.77 to $20.73. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These shares are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein. These sales were executed in multiple trades at prices ranging from $19.81 to $20.19. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $19.82 to $20.41. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. This Form 4/A to the Form 4 filed with the Securities and Exchange Commission on January 9, 2020 is being amended and restated in its entirety to correct the aggregate number of securities beneficially owned by Versant VI in Table I, Column 5. As a result of the transactions reported herein, the Reporting Persons no longer beneficially own greater than 10% of the outstanding shares of the Issuer, and therefore are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended. This filing constitutes an exit filing for the Reporting Persons. VERSANT VENTURE CAPITAL VI, L.P. By: Versant Ventures VI GP, L.P., its general partner By: Versant Ventures VI GP-GP, LLC, its general partner By: /s/ Robin L. Praeger, Managing Director 2020-07-10 VERSANT VENTURES VI GP, L.P. By: Versant Ventures VI GP-GP, LLC, its general partner Its: General Partner By: /s/ Robin L. Praeger, Managing Director 2020-07-10 VERSANT VENTURES VI GP-GP, LLC By: /s/ Robin L. Praeger, Managing Director 2020-07-10